2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 80

Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry
Abstract Number: 2462

Centrosomal Protein 70kDa Is Down-Regulated By Decoy Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts
Abstract Number: 2655

Cerebral Small Vessel Disease in Systemic Lupus Erythematosus: Histopathological Study
Abstract Number: 2827

Cervical Spine Fracture and Mortality in Ankylosing Spondylitis
Abstract Number: 2359

CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Abstract Number: 1903

Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Abstract Number: 1579

Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Abstract Number: 2270

Changes in Cerebral Blood Flow Velocity in Patients with Familial Mediterranean Fever
Abstract Number: 207

Changes in Knee Compartment Distriubtion of Cartilage Loss and Bone Marrow Lesions over 7 Years: The MOST Study
Abstract Number: 2861

Changes in Knee Kinematics from a 6-Week Hip and Trunk Strengthening Program for Persons with Patellofemoral Osteoarthritis
Abstract Number: 1020

Changes in Peripheral Blood Immune Cell Composition in Osteoarthritis
Abstract Number: 2259

Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis
Abstract Number: 1964

Changes in Soluble CD18 Reflect Latency in the Immune System and Predict Radiographic Progression in Early Rheumatoid Arthritis
Abstract Number: 2254

Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
Abstract Number: 1435

Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].